Profile data is unavailable for this security.
About the company
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, marketing and sale of treatments and therapies, primarily for rare and orphan diseases. Its lead product, Endari (prescription grade L-glutamine oral powder) helps to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Its product pipeline includes ELS001/ELS007, ELS004, ELS005, ELS003, and ELS002. The Company, through Kainos Medicine, Inc. (Kainos), has a license in the territory encompassing the United States, the United Kingdom, and the European Union to patent rights, know-how, and other intellectual property relating to Kainos’s IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, including leukemia, lymphoma, and solid tumor cancers. The Company has also developed chondrocyte and osteoblast cell sheets using human mesenchymal stem cells.
- Revenue in USD (TTM)11.89m
- Net income in USD-7.29m
- Incorporated1987
- Employees34.00
- LocationEmmaus Life Sciences Inc21250 HAWTHORNE BOULEVARD, SUITE 800TORRANCE 90503United StatesUSA
- Phone+1 (310) 214-0065
- Fax+1 (310) 214-0075
- Websitehttps://www.emmausmedical.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bio Path Holdings Inc | 0.00 | -11.18m | 546.12k | 10.00 | -- | -- | -- | -- | -1.71 | -1.71 | 0.00 | -0.866 | 0.00 | -- | -- | 0.00 | -611.66 | -81.00 | -- | -90.58 | -- | -- | -- | -- | -- | -65.76 | -- | -- | -- | -- | 38.46 | -- | -- | -- |
| Novelstem International Corp | 3.00k | 2.31m | 562.58k | 15.00 | 0.2495 | -- | -- | 187.53 | 0.0481 | 0.0481 | 0.00006 | -0.0438 | 0.0281 | -- | 0.80 | -- | 630.69 | -- | -- | -- | -- | -- | 22,424.33 | -- | -- | -- | -- | -- | 0.00 | -- | 22.79 | -- | -- | -- |
| Helix BioMedix Inc | 2.07m | -2.58m | 609.46k | 8.00 | -- | 0.3887 | -- | 0.295 | -15.60 | -15.60 | 12.48 | 6.95 | 0.8047 | 1.87 | 4.55 | 258,238.80 | -100.64 | -146.31 | -120.73 | -173.57 | 68.96 | 30.80 | -125.06 | -527.12 | 1.69 | -14.57 | 0.00 | -- | 122.07 | 92.80 | 67.73 | -- | -29.08 | -- |
| Avenue Therapeutics Inc | 1.40m | -3.74m | 609.91k | 2.00 | -- | 0.1715 | -- | 0.4344 | -1.55 | -1.55 | 0.50 | 1.12 | 0.4422 | -- | -- | 702,000.00 | -119.06 | -159.81 | -122.59 | -215.40 | -- | -- | -269.23 | -- | -- | -- | 0.00 | -- | -- | -- | -12.29 | -- | -- | -- |
| Hepion Pharmaceuticals Inc | 0.00 | -9.17m | 662.36k | 22.00 | -- | 0.4065 | -- | -- | -13.39 | -13.39 | 0.00 | 0.2861 | 0.00 | -- | -- | -- | -245.96 | -65.13 | -417.51 | -73.82 | -- | -- | -- | -- | -- | -5.25 | 0.0606 | -- | -- | -- | 73.04 | -- | -- | -- |
| Protagenic Therapeutics Inc | -100.00bn | -100.00bn | 773.95k | 1.00 | -- | -- | -- | -- | -- | -- | -- | -2.43 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.2945 | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Lipella Pharmaceuticals Inc | 389.79k | -5.33m | 881.42k | 5.00 | -- | 0.5925 | -- | 2.26 | -2.41 | -2.41 | 0.1286 | 0.3219 | 0.1729 | -- | 25.08 | 77,958.00 | -236.36 | -101.93 | -336.65 | -125.09 | -- | -- | -1,367.34 | -592.18 | -- | -- | 0.00 | -- | 19.29 | -5.04 | -8.60 | -- | -- | -- |
| Emmaus Life Sciences Inc | 11.89m | -7.29m | 887.73k | 34.00 | -- | -- | -- | 0.0746 | -0.1141 | -0.1141 | 0.1862 | -0.9315 | 0.4945 | 0.6596 | 3.13 | 349,794.10 | -30.31 | -14.68 | -- | -211.99 | 92.17 | 90.14 | -61.29 | -32.65 | 0.0557 | -0.1912 | -- | -- | -43.73 | -6.05 | -72.86 | -- | -27.52 | -- |
| PMGC Holdings Inc | 285.95k | -4.48m | 895.35k | 2.00 | -- | 0.0386 | -- | 3.13 | -57.57 | -129.01 | 3.93 | 45.64 | 0.0219 | 0.373 | 1.98 | 142,975.00 | -34.29 | -- | -48.32 | -- | 27.29 | -- | -1,567.42 | -- | 1.77 | -32.16 | 0.2734 | -- | -- | -- | -142.45 | -- | -- | -- |
| CeCors Inc | -100.00bn | -100.00bn | 996.24k | 6.00 | -- | -- | -- | -- | -- | -- | -- | -0.0163 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 22.70 | -- | -- | -- |
| CERo Therapeutics Holdings Inc | 0.00 | -49.19m | 1.01m | 8.00 | -- | -- | -- | -- | -175.56 | -175.56 | 0.00 | -3.04 | 0.00 | -- | -- | 0.00 | -282.75 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -52.12 | -- | -- | -- |
| Herborium Group Inc | 340.33k | -318.65k | 1.09m | 2.00 | -- | -- | -- | 3.21 | -0.3492 | -0.3492 | 0.3672 | -1.16 | 2.32 | 3.89 | 25.94 | -- | -216.97 | -490.56 | -- | -- | 58.31 | 56.36 | -93.63 | -186.81 | 0.0331 | -39.14 | -- | -- | 19.45 | -18.15 | 120.44 | -- | -- | -- |
| Halberd Corp | 281.24k | 25.34k | 1.13m | 3.00 | 0.6897 | -- | 44.61 | 4.02 | 0.0023 | 0.0023 | 0.0018 | -0.0002 | 0.1449 | 0.0303 | 2.52 | -- | 1.31 | -- | 4.58 | -- | 50.00 | -- | 9.01 | -- | 0.2661 | 1.35 | 1.02 | -- | 271.52 | -- | -60.11 | -- | -- | -- |
| Aditxt Inc | 5.95k | -42.24m | 1.16m | 26.00 | -- | -- | -- | 194.32 | -13,234.74 | -13,234.74 | 0.3444 | -151.86 | 0.0003 | 1.54 | 0.0304 | 228.85 | -207.03 | -148.78 | -- | -279.11 | -1,134.96 | -- | -724,419.70 | -8,283.15 | 0.02 | -12.48 | -- | -- | -79.23 | -- | -23.40 | -- | -- | -- |
